


ABSTRACT

The invention is directed to compounds of Formulae I, II, III or IV:



5

wherein R, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, A<sub>1</sub> and A<sub>2</sub> are set forth in the specification, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially VEGFR-2 (KDR), c-fms, c-met and tie-2 kinases. The invention is also directed toward methods of preparation of the compounds of Formulae I, II, III and IV.

10

15